Core Points - The company held its sixth supervisory board's fifth meeting on August 26, 2025, to review and approve the 2025 semi-annual report and its summary [1][2] - The supervisory board confirmed that the report complies with relevant laws, regulations, and the company's internal rules, ensuring the information is true, accurate, and complete [1] - The voting results showed unanimous approval with 3 votes in favor, 0 against, and 0 abstentions for the proposal [2] Summary by Sections - **Meeting Details** - The meeting was conducted via telecommunication and attended by three supervisors, with the chairman presiding [1] - The meeting adhered to the requirements of the Company Law of the People's Republic of China and the company's articles of association [1] - **Report Review** - The supervisory board reviewed the 2025 semi-annual report and its summary, concluding that the content accurately reflects the company's operational and financial status [1] - The report was found to meet the requirements set by the Shenzhen Stock Exchange and the China Securities Regulatory Commission [1] - **Voting Outcome** - The proposal regarding the semi-annual report was passed with a unanimous vote of 3 in favor [2]

Group 1 - The company announced that its sixth supervisory board's fifth meeting approved the proposal for the full text and summary of the 2025 semi-annual report [2]

Core Viewpoint - Lideman announced the approval of the full text and summary of the 2025 semi-annual report by its sixth board of directors at the fifth meeting [2] Group 1 - The announcement was made on the evening of August 26 [2] - The decision was made during a board meeting [2] - The report pertains to the company's performance for the first half of 2025 [2]

Core Viewpoint - Lide Man (300289.SZ) reported a decline in revenue and an increase in net losses for the first half of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 160 million yuan, representing a year-on-year decrease of 14.80% [1] - The net loss attributable to shareholders of the listed company was 4.2452 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 10.5526 million yuan, which expanded by 191.60% year-on-year [1] - The basic loss per share was 0.0078 yuan [1]

Group 1 - Lidman (SZ 300289, closing price: 8.89 yuan) announced on August 26 that its sixth fifth board meeting was held via communication method, discussing the proposal for the full text and summary of the 2025 semi-annual report [1] - For the year 2024, Lidman's revenue composition is as follows: 90.84% from the biopharmaceutical industry, 8.98% from property leasing, and 0.17% from services [1] - As of the report date, Lidman's market capitalization is 4.8 billion yuan [1] Group 2 - The pet industry is experiencing a significant boom, with a market size of 300 billion yuan, leading to a surge in stock prices of related listed companies [1]

Core Viewpoint - Lideman (300289) reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved operating revenue of 160 million yuan in the first half of 2025, representing a year-on-year decrease of 14.80% [1] - The net profit for the same period was -4.2452 million yuan, reflecting a substantial year-on-year decline of 800.43% [1] - Basic earnings per share were reported at -0.0078 yuan [1] - The weighted average return on equity (ROE) stood at -0.26% [1]

Core Viewpoint - Lideman (300289.SZ) reported a decline in revenue and an increase in net losses for the first half of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 160 million yuan, representing a year-on-year decrease of 14.80% [1] - The net loss attributable to shareholders of the listed company was 4.2452 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 10.5526 million yuan, which expanded by 191.60% year-on-year [1] - The basic loss per share was 0.0078 yuan [1]

证券代码：300289 证券简称：利德曼 公告编号：2025-038 北京利德曼生化股份有限公司 2025年半年度报告披露提示性公告 北京利德曼生化股份有限公司 董 事 会 2025 年 8 月 26 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开第六届董事会第五次会议、第六届监事会第五次会议，审 议通过了《关于 2025 年半年度报告全文及摘要的议案》。 为使投资者全面了解本公司的经营成果、财务状况及未来发展规 划，公司《2025 年半年度报告》及《2025 年半年度报告摘要》于 2025 年 8 月 27 日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露，敬请投资者注意查阅！ 特此公告。 ...

编制单位：北京利德曼生化股份有限公司 单位：人民币 元 北京利德曼生化股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 法定代表人：尧子 主管会计工作的负责人：欧阳旭 会计机构负责人：欧阳旭 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市 | 上市公司核 | 2025 年期初 | 年上半年度占用 2025 2025年上半年度 | 2025年上半年度 | 2025 年 6 月末 | 占用形成原因 | 占用性 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 算的会计科 | | 累计发生金额（不含 占用资金的利息 | 偿还累计发生金 | | | | | | | 公司的关联关系 | 目 | 占用资金余额 | 利息） （如有） | 额 | 占用资金余额 | | 质 | | 控股股东、实际控制人及其附属企 | — | — | — | | | | | | — | | 业 | | | | | | | | | | | 小计 | — | — | — | | | | | | — | | 前控股股东 ...

证券代码：300289 证券简称：利德曼 公告编号：2025-035 北京利德曼生化股份有限公司 第六届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）第六届监事会 第五次会议（以下简称"本次会议"）通知于 2025 年 8 月 15 日以电 子邮件方式向全体监事发出，与会的各位监事已知悉与所审议事项相 关的必要信息。本次会议于 2025 年 8 月 26 日在北京市北京经济技术 开发区兴海路 5 号公司二层会议室以通讯方式召开。出席会议的监事 应到 3 名，亲自出席监事 3 名，本次会议由公司监事会主席林冠宇先 生主持。本次会议的召开符合《中华人民共和国公司法》及《公司章 程》等法律、法规和内部制度的规定。会议以投票表决方式审议通过 以下议案： 一、审议通过《关于 2025 年半年度报告全文及摘要的议案》 公司监事会对《2025 年半年度报告》及《2025 年半年度报告摘 要》进行了审核，提出如下审核意见： 1、公司董事会编制和审核公司 2025 年半年度报告的程序符合法 律法规、中国证 ...